dr. awan on remaining questions with btk inhibitors and anti-cd20 combos in cll
Published 4 years ago • 105 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:34
dr. awan on future of combo regimens in cll treatment paradigm
-
1:22
dr. ghosh on unanswered questions with btk inhibitors in cll/sll
-
7:29
btk inhibitor with vs without a cd20-targeted antibody
-
3:37
identifying patients with cll at a high risk of developing cardiotoxicity with btk inhibitors
-
1:22
dr. awan on utilizing acalabrutinib in cll
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
1:06
dr. sharman on remaining challenges with btk inhibitors in cll
-
5:32
frontline antibodies with btk inhibitors for cll
-
6:52
comparison of btk inhibitors for cll
-
1:53
dr. awan on novel strategies under exploration in relapsed/refractory cll
-
4:13
sequencing therapy in cll: btk and bcl2 inhibitors
-
18:43
btk inhibitors for chronic lymphocytic leukemia: rapid-fire highlights from the past year
-
1:25:33
customizing care in cll with btk inhibitors
-
0:48
advances in non-covalent btk inhibitors for cll: bruin study update
-
3:57
btk inhibitors in chronic lymphocytic leukemia
-
1:13:17
cll care with btk inhibitors: selection, safety, and sequencing across the disease continuum
-
20:48
cll: btk inhibitors vs chemoimmunotherapy as initial treatment
-
3:25
btk inhibitors in cll: treatment selection
-
2:58
updates on non-covalent btk inhibitors and their place in cll treatment